World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
56
Citations
11782
World Ranking
3719
National Ranking
36

Mads Hald Andersen publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mads Hald Andersen sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 299 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mads Hald Andersen D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mads Hald Andersen sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 56 D-Index — 26th percentile

26% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Mads Hald Andersen is affiliated with Copenhagen University Hospital in Denmark and has a research focus primarily within Medicine and Immunology and Microbiology. Their scholarly contributions extend across several subfields including Immunology, Oncology, Hematology, Genetics, and Molecular Biology. The areas of study most frequently addressed in their work encompass Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Immune Cells in Cancer, Immune Cell Function and Interaction, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, and CAR-T Cell Therapy Research.

Andersen has contributed to numerous publications, with recent notable papers including:

  • "A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma" (2021, Nature Medicine)
  • "Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition" (2025, Journal of Hematology & Oncology)
  • "Tumor microenvironment antigens" (2022, Seminars in Immunopathology)
  • "Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade" (2021, Cancer Immunology Research)
  • "Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms" (2021, Frontiers in Oncology)

Frequent co-authors associated with Andersen's work include:

  • Morten Orebo Holmström
  • Inge Marie Svane
  • Evelina Martinenaite
  • Jacob Handlos Grauslund
  • Vibe Skov

Their publications are commonly found in these venues:

  • Frontiers in Immunology
  • Regular and Young Investigator Award Abstracts
  • Journal for ImmunoTherapy of Cancer
  • Cancers
  • OncoImmunology

Best Publications

  • Cytotoxic T Cells

    Mads Hald Andersen;David Schrama;Per thor Straten;Jürgen C. Becker

  • The effect of short-chain fatty acids on human monocyte-derived dendritic cells

    Claudia Nastasi;Marco Candela;Charlotte Menné Bonefeld;Carsten Geisler

  • Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients

    Mads Hald Andersen;Lars Østergaard Pedersen;Jürgen C. Becker;Per thor Straten

  • Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients

    Mads Hald Andersen;Lars Ø. Pedersen;Barbara Capeller;Eva-Bettina Bröcker

  • Oncogenic cancer/testis antigens: prime candidates for immunotherapy

    Morten F. Gjerstorff;Mads H. Andersen;Henrik J. Ditzel

  • Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

    Rikke Andersen;Marco Donia;Eva Ellebaek;Troels Holz Borch

  • Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

    Lotte Engell-Noerregaard;Troels Holz Hansen;Mads Hald Andersen;Per thor Straten

  • Immune-suppressive properties of the tumor microenvironment

    Jürgen C. Becker;Mads Hald Andersen;David Schrama;Per thor Straten

  • The universal character of the tumor-associated antigen survivin.

    Mads Hald Andersen;Inge Marie Svane;Jürgen C. Becker;Per thor Straten

  • Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.

    Marion Wobser;Petra Keikavoussi;Volker Kunzmann;Markus Weininger

  • Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

    Eva Ellebaek;Trine Zeeberg Iversen;Niels Junker;Marco Donia;Marco Donia

  • A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

    Unknown

  • Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.

    Mads Hald Andersen;Jordi Espuny Bonfill;Anne Neisig;Gemma Arsequell

  • Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

    Rikke Bæk Sørensen;Sine Reker Hadrup;Inge Marie Svane;Mads Christian Hjortsø

  • Regulators of apoptosis: suitable targets for immune therapy of cancer

    Mads Hald Andersen;Jürgen C. Becker;Per thor Straten

  • Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity

    Marco Donia;Marco Donia;Rikke Andersen;Julie Westerlin Kjeldsen;Paolo Fagone

  • Survivin--a universal tumor antigen.

    M H Andersen;Straten P thor

  • Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.

    Kerstin Otto;Mads Hald Andersen;Andreas Eggert;Petra Keikavoussi

  • Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase

    Trine Zeeberg Iversen;Lotte Engell-Noerregaard;Eva Ellebaek;Rikke Andersen

  • Butyrate and propionate inhibit antigen-specific CD8+ T cell activation by suppressing IL-12 production by antigen-presenting cells

    Claudia Nastasi;Simon Fredholm;Andreas Willerslev-Olsen;Morten Hansen

  • Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

    Eva Ellebaek;Lotte Engell-Noerregaard;Trine Zeeberg Iversen;Thomas Moerch Froesig;Thomas Moerch Froesig

  • Identification of novel survivin-derived CTL epitopes.

    Sine Reker;Anders Meier;Lars Holten-Andersen;Inge Marie Svane

Frequent Co-Authors

Per thor Straten
Per thor Straten University of Copenhagen
Inge Marie Svane
Inge Marie Svane Copenhagen University Hospital
Jürgen C. Becker
Jürgen C. Becker University of Duisburg-Essen
Marco Donia
Marco Donia Copenhagen University Hospital
Morten Hartvig Hansen
Morten Hartvig Hansen University of Southern Denmark
Sine Reker Hadrup
Sine Reker Hadrup Technical University of Denmark
Niels Ødum
Niels Ødum University of Copenhagen
Anders Woetmann
Anders Woetmann University of Copenhagen
Carsten Geisler
Carsten Geisler University of Copenhagen
Eckhart Kämpgen
Eckhart Kämpgen University of Erlangen-Nuremberg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open diverse career opportunities. Many students start with a foundational nursing degree before progressing to specialized roles. Programs like the easiest ABSN to get into offer accelerated pathways for individuals transitioning into nursing, helping them build essential skills quickly.

Once a nursing foundation is established, advanced certifications such as acute care NP certification allow practitioners to specialize in critical care environments, complementing their immunology knowledge with hands-on expertise in managing complex conditions.

For those without prior nursing experience, online RN programs for non nurses in Florida provide flexible and accessible routes into the nursing profession. These programs are designed to accommodate diverse backgrounds and offer foundational training relevant to various healthcare fields, including immunology.

Moreover, accelerated programs like accelerated nurse practitioner program help students quickly move into advanced practice roles, where they can integrate immunological principles with clinical expertise. Such pathways support a smooth transition from education to impactful careers in healthcare.

Best Scientists Citing Mads Hald Andersen

Trending Scientists

Recently Published Articles